Hanmi Pharm shares down on FDA panel's disapproval of fast-tracking poziotinib
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Spectrum announced on Thursday that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 9-4 that the current benefits of the drug did not outweigh its risks.
Shares of Hanmi were 0.8 percent lower at 237,500 won ($168) at 1:00 p.m. Friday.
Poziotinib has been tested for the treatment of patients with previously treated locally advanced or metastatic NSCLC harboring HER2 exon 20 insertion mutations.
ODAC is an independent panel of experts that reviews and evaluates efficacy and safety data of investigational cancer drugs. The committee makes recommendations to the FDA, but the recommendations are not binding and the final decision on product approval will be made solely by the FDA.
The FDA will review all the opinions from experts and make a final approval decision by November 24 according to the Prescription Drug User Fee Act (PDUFA).
“We are disappointed by the outcome of the ODAC meeting, as patients with NSCLC HER2 exon 20 insertion mutations are in need of additional effective and safe therapies. We plan to carefully evaluate our options for this program as we approach the PDUFA date,” said Tom Riga, president and CEO of Spectrum Pharmaceuticals, in a statement.
The ODAC recommendation followed an unfavorable statement from the FDA’s scientist session where the majority said poziotinib may not provide a meaningful advantage over available therapies and additional analyses will be required. The scientists said the data provided shows a low 28 percent overall response rate (ORR) and the safety profile is poor.
Spectrum and Hanmi immediately refuted the statement, saying the drug is an innovative treatment that can serve well as one of many treatment options for patients with no other cure.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Nexon late founder Kim’s teenage daughter becomes world’s youngest billionaire - Pulse by Maeil Business News Korea
- S. Korea attracts $1.15 bn investment in chip, battery from seven NA firms - Pulse by Maeil Business News Korea
- KRW at weakest vs USD since crisis times draw crisis-like response from Seoul authorities - Pulse by Maeil Business News Korea
- S. Korean game developers’ cash reserves shrink over 40% in 6 months - Pulse by Maeil Business News Korea
- Korea and U.S. jointly form $215 mn fund to help Korean startups go global - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 아시아 최초 ‘다인종·다문화 국가’ 한국 [편집장 레터]
- NCT 태일, 불미스러운 일로 팀 탈퇴…SM “엄중함 인지”[공식입장][전문] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이